Search results
Results from the WOW.Com Content Network
Overdiagnosis is the diagnosis of disease that will never cause symptoms or death during a patient's ordinarily expected lifetime [1] and thus presents no practical threat regardless of being pathologic. Overdiagnosis is a side effect of screening for early forms of disease.
A biophysical profile (BPP) is a prenatal ultrasound evaluation of fetal well-being involving a scoring system, [1] with the score being termed Manning's score. [2] It is often done when a non-stress test (NST) is non reactive, or for other obstetrical indications. The "modified biophysical profile" consists of the NST and amniotic fluid index ...
The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk .
Lead time is the duration of time between the detection of a disease (by screening or based on new experimental criteria) and its usual clinical presentation and diagnosis (based on traditional criteria). [1] For example, it is the time between early detection by screening and the time when diagnosis would have been made clinically (without ...
There are three purposes of prenatal diagnosis: (1) to enable timely medical or surgical treatment of a condition before or after birth, (2) to give the parents the chance to abort a fetus with the diagnosed condition, and (3) to give parents the chance to prepare psychologically, socially, financially, and medically for a baby with a health problem or disability, or for the likelihood of a ...
[1] [2] [3] MoM was originally used as a method to normalize data from participating laboratories of Alpha-fetoprotein (AFP) so that individual test results could be compared. 35 years later, it is the established standard for reporting maternal serum screening results. [4] An MoM for a test result for a patient can be determined by the following:
The index was developed by Mary Charlson and colleagues in 1987, but the methodology has been adapted several times since then based on the findings of additional studies. [5] Many variations of the Charlson comorbidity index have been presented, including the Charlson/Deyo, Charlson/Romano, Charlson/Manitoba, and Charlson/D'Hoores comorbidity ...
[80] Estimates of overdiagnosis associated with mammography have ranged from 1% to 54%. [85] In 2009, Peter C. Gotzsche and Karsten Juhl Jørgensen reviewed the literature and found that 1 in 3 cases of breast cancer detected in a population offered mammographic screening is over-diagnosed. [ 86 ]